Here's information about Genomic Health, formatted as requested:

Genomic Health (Historical Data) on Google Finance

Genomic Health, now part of Exact Sciences, was a molecular diagnostics company focused on developing and commercializing genomic-based clinical tests that analyze the underlying biology of cancer, helping physicians make individualized treatment decisions. While Genomic Health is no longer a standalone publicly traded company, historical data related to its stock performance remains accessible through Google Finance and other financial data providers.

Key Focus and Products

Genomic Health's primary product was the Oncotype DX^® portfolio of tests. These tests analyzed the activity of specific genes within a tumor sample to predict the likelihood of cancer recurrence and/or the benefit from certain treatments. The tests were primarily used in breast, colon, and prostate cancer:

• Oncotype DX Breast Recurrence Score^®: A widely adopted test used to predict the likelihood of distant recurrence in early-stage, estrogen receptor-positive (ER+), HER2-negative breast cancer and to predict the benefit from chemotherapy.
• Oncotype DX Colon Recurrence Score^®: Used to predict the likelihood of recurrence in stage II colon cancer patients and to help guide decisions about adjuvant chemotherapy.
• Oncotype DX Genomic Prostate Score^®: Used to predict the aggressiveness of prostate cancer and help guide treatment decisions, such as whether or not to pursue active surveillance versus more aggressive interventions.

Acquisition by Exact Sciences

In November 2019, Exact Sciences Corporation acquired Genomic Health for approximately $2.8 billion in cash and stock. This acquisition significantly expanded Exact Sciences' presence in the cancer diagnostics market, adding Genomic Health's established Oncotype DX tests to Exact Sciences' portfolio, which already included the Cologuard^® colorectal cancer screening test.

Historical Significance and Impact

Genomic Health played a pivotal role in the advancement of personalized cancer care. By providing genomic information about individual tumors, the Oncotype DX tests enabled doctors to tailor treatment plans to each patient's specific needs. This helped to avoid unnecessary treatments, such as chemotherapy, in patients who were unlikely to benefit, reducing side effects and healthcare costs. The adoption of these tests influenced treatment guidelines and became a standard of care for many patients with early-stage cancers.

Accessing Historical Data on Google Finance

While Genomic Health's stock ticker symbol (GHDX) is no longer actively traded, users can still find historical stock price data, charts, and financial reports on Google Finance and other financial platforms. This data can be useful for researchers, investors, and analysts studying the company's past performance, market trends, and the impact of the acquisition by Exact Sciences. When searching, be sure to specify the relevant time period before the acquisition to view Genomic Health's independent performance. Keep in mind that past performance is not indicative of future results.